Cancer and Leukemia Group B Release: Data from Phase II Clinical Trial of Galiximab in Combination with Rituximab in Patients with Previously Untreated Follicular Lymphoma Presented at International Conference on Malignant Lymphoma
6/9/2008 8:56:34 AM
LUGANO, Switzerland--(BUSINESS WIRE)--The Cancer and Leukemia Group B (CALGB) today announced data from a phase II clinical trial showing that 70 percent of patients with previously untreated follicular lymphoma responded to treatment with galiximab, an investigational anti-CD80 monoclonal antibody, when given in combination with rituximab. Of the 61 patients in the study, 44 percent achieved a complete response and 26 percent had a partial response. The data were presented at the 10th International Conference on Malignant Lymphoma (ICML).
comments powered by